Scholarlink

Background <p>Growing evidence supports chronic pain (CP) as a risk factor for Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). We examined whether CP is associated with longitudinal worsening of AD-related biomarkers, brain structure, and cognition, and whether effects differ by APOE-ε4 status.</p> Methods <p>Data were drawn from 1,493 participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) without baseline dementia (mean age = 72.4 ± 7.19 years; 48% female). Linear mixed-effects models tested longitudinal change in cerebrospinal fluid (CSF) and positron emission tomography (PET) amyloid-β (Aβ) and phosphorylated tau (p-tau181), structural MRI indices (AD-related cortical signature, hippocampal and entorhinal volumes, precuneus thickness), and cognitive outcomes (episodic memory, executive function, Mini-Mental State Examination [MMSE]). Models included fixed effects of CP status, APOE-ε4 status, time (years since baseline), and their two-way and three-way interactions, adjusting for age, sex, education, baseline Aβ positivity status, and time-varying depressive symptoms.</p> Results <p>At baseline, 30% of participants (<i>n</i> = 452) reported CP and 45% (<i>n</i> = 666) were APOE-ε4 carriers. CP and APOE-ε4 status did not independently predict baseline CSF Aβ42/Aβ40, PET Aβ burden, or CSF p-tau181. Longitudinally, the CP+/ε4 + group showed greater AD-like changes in CSF Aβ42/Aβ40 and CSF p-tau181, thinning of the precuneus (β=-0.09, <i>p</i>&lt;.001) and faster decline in episodic memory (β=-0.08, <i>p</i>&lt;.001), compared to all other groups. Many of these associations remained when excluding participants with MCI or restricting to Aβ-negative participants.</p> Conclusions <p>The combination of CP and APOE-ε4 carriership was associated with greater longitudinal worsening of brain structure and cognitive function, even among individuals who were Aβ-negative at baseline. These findings provide in vivo evidence that CP is associated with greater AD-related worsening over time in the context of genetic susceptibility. As evidence accumulates, CP may warrant recognition as a risk factor in dementia prevention frameworks, though causal inferences require further study.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Chronic pain as a risk factor for Alzheimer’s disease pathology: a longitudinal ADNI study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月3日

查看全文
  • Tyler R. Bell,
  • Carol E. Franz,
  • Christine Fennema-Notestine,
  • Erin E. Sundermann,
  • Shelby B. Hughes,
  • Matthew S. Panizzon,
  • Imanuel Lerman,
  • Jeremy A. Elman,
  • William S. Kremen

摘要

Background

Growing evidence supports chronic pain (CP) as a risk factor for Alzheimer’s disease and Alzheimer’s disease-related dementias (AD/ADRD). We examined whether CP is associated with longitudinal worsening of AD-related biomarkers, brain structure, and cognition, and whether effects differ by APOE-ε4 status.

Methods

Data were drawn from 1,493 participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) without baseline dementia (mean age = 72.4 ± 7.19 years; 48% female). Linear mixed-effects models tested longitudinal change in cerebrospinal fluid (CSF) and positron emission tomography (PET) amyloid-β (Aβ) and phosphorylated tau (p-tau181), structural MRI indices (AD-related cortical signature, hippocampal and entorhinal volumes, precuneus thickness), and cognitive outcomes (episodic memory, executive function, Mini-Mental State Examination [MMSE]). Models included fixed effects of CP status, APOE-ε4 status, time (years since baseline), and their two-way and three-way interactions, adjusting for age, sex, education, baseline Aβ positivity status, and time-varying depressive symptoms.

Results

At baseline, 30% of participants (n = 452) reported CP and 45% (n = 666) were APOE-ε4 carriers. CP and APOE-ε4 status did not independently predict baseline CSF Aβ42/Aβ40, PET Aβ burden, or CSF p-tau181. Longitudinally, the CP+/ε4 + group showed greater AD-like changes in CSF Aβ42/Aβ40 and CSF p-tau181, thinning of the precuneus (β=-0.09, p<.001) and faster decline in episodic memory (β=-0.08, p<.001), compared to all other groups. Many of these associations remained when excluding participants with MCI or restricting to Aβ-negative participants.

Conclusions

The combination of CP and APOE-ε4 carriership was associated with greater longitudinal worsening of brain structure and cognitive function, even among individuals who were Aβ-negative at baseline. These findings provide in vivo evidence that CP is associated with greater AD-related worsening over time in the context of genetic susceptibility. As evidence accumulates, CP may warrant recognition as a risk factor in dementia prevention frameworks, though causal inferences require further study.